Overview

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

Status:
Completed

Trial end date:
2008-09-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether donepezil HCl is effective and safe in improving cognitive dysfunction exhibited by children and adolescents with Down syndrome (DS). Effectiveness will be measured by rating communication, daily living skills, and social skills and relationships in subjects aged 10 to 17.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Pfizer

Treatments:

Donepezil